- Published on
Infectious Disease and Microbiology: Herpes Zoster (Shingles)
Herpes zoster, commonly known as shingles, is a localized skin and nerve infection caused by reactivation of the Varicella zoster virus, the same virus responsible for chickenpox. After a primary infection, the virus remains dormant in sensory nerve ganglia for years. Reactivation later in life leads to herpes zoster, typically presenting as a painful, vesicular rash confined to a specific dermatome.
Epidemiologically, herpes zoster occurs worldwide and affects approximately 20% of individuals during their lifetime. The incidence increases significantly with age, particularly in those over 50 years. Nearly 90% of adults have evidence of prior VZV infection, placing them at risk for reactivation. Immunocompromised individuals—such as those with HIV infection, malignancies, or those receiving immunosuppressive therapy—are at particularly high risk and may develop more severe or disseminated disease.
The pathophysiology involves reactivation of latent virus within dorsal root or cranial nerve ganglia. The virus travels along sensory nerves to the skin, producing inflammation and the characteristic painful rash. The exact triggers for reactivation are not fully understood but are strongly associated with declining cell-mediated immunity, especially in aging or immunosuppressed individuals.
Clinically, patients typically present with localized pain, burning, or tingling in a dermatomal distribution, often preceding the rash by a few days. This is followed by the appearance of grouped vesicles on an erythematous base, usually confined to one side of the body. The thoracic and lumbar dermatomes are most commonly affected. Involvement of the trigeminal nerve may lead to ocular complications (herpes zoster ophthalmicus), while involvement of the geniculate ganglion can result in Ramsay Hunt syndrome, characterized by ear lesions and facial paralysis.
Diagnosis is primarily clinical, based on the typical unilateral dermatomal rash and associated pain. Laboratory tests such as PCR or serology can confirm the diagnosis but are rarely necessary in routine cases. Imaging or lumbar puncture may be required if central nervous system involvement is suspected.
Treatment focuses on antiviral therapy and pain management. First-line therapy includes oral acyclovir, while alternatives such as valacyclovir or famciclovir offer improved dosing convenience. In severe cases or immunocompromised patients, intravenous antivirals may be required. Adjunctive therapies, including analgesics and sometimes corticosteroids, may help reduce acute symptoms, although steroids do not prevent long-term complications.
The prognosis is generally good in immunocompetent individuals, but complications are not uncommon. The most significant is postherpetic neuralgia, a chronic pain condition that can persist long after the rash resolves, particularly in older adults. Other complications include secondary bacterial infection, ocular damage potentially leading to blindness, and, in severe cases, systemic involvement such as pneumonitis, hepatitis, or central nervous system disease.
Prevention includes vaccination against VZV, which reduces both the incidence of herpes zoster and the risk of postherpetic neuralgia. In high-risk individuals, prophylactic antivirals or immunoglobulin may be used following exposure.
0 Comments
